Morgan Stanley lowered the firm’s price target on Corebridge to $31 from $33 and keeps an Equal Weight rating on the shares. In Q2, most life insurance companies reported earnings that exceeded expectations, the analyst tells investors. Despite the strong results, the firm remains incrementally negative on life insurers due to the potential compression on spread-based income products and market volatility that has emerged in the past few weeks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBG:
- Corebridge reports Q2 operating EPS $1.13, consensus $1.09
- Corebridge Financial put volume heavy and directionally bearish
- Corebridge price target lowered to $38 from $40 at BofA
- Corebridge price target raised to $35 from $29 at UBS
- Corebridge Financial call volume above normal and directionally bullish